

Mupirocin resistance in Staphylococcus aureus in pediatric patients for ten years



Hwanhee Park^{1,2}, Doo Ri Kim¹, Kyung-Ran Kim^{1,3}, Jong Min Kim⁴, Hee Jae Huh⁵, Nam Yong Lee⁵, Yae-Jean Kim¹

¹Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ²Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea (current affiliation), ³Department of Pediatrics, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea (current affiliation), ⁴Department of Pediatrics, Myungji Hospital, Goyang, Korea

⁵Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Reckground: Mupirocin has been recommended for decolonization in methicillin-resistant *Staphylococcus aureus* (MRSA) carriers for recurrent skin and soft tissue infections and treatment for impetigo. However, the indiscriminate use of mupirocin resistance, associated with decolonization failure. The aim of the study was to investigate the epidemiology of mupirocin resistance and to identify clinical characteristics among children in a single center. **Method:** From January 2011 to October 2020, we retrospectively analyzed the epidemiology of antibiotic resistance and clinical characteristics of pediatric patients under 19 years old in whom *S. aureus* was firstly isolated at any body site. **Result:** Of the 3,414 *S. aureus* isolates, 46% (1569/3414) were mupirocin resistant, Among MRSA, Mupirocin-resistant (MupR) was 22.6% (354/1569), and among methicillin-sensitive *S. aureus* (MSSA), MupR was 18.3 (338/1845) (*P*<0.001). The median age of MupR MRSA patients was 0.14 years (interquartile range 2.0-8.1) (*P*=0.000). Of 692 MupR S. aureus, 94.2% (652/692) were mainly detected in the skin. MupR MRSA was most frequently isolated in the neona tal intensive care unit (40.1%, 142/354), but MupR MSSA was most frequently isolated in the outpatient setting (81.4%, 275/338) (*P*<0.001). Of these, 43% (119/275) patients were diagnosed with atopic dermatitis. By age, mupR MRSA was the more commonly isolated in infants younger than one year (77.4%, 274/354), and MupR MSSA and MSSA showed an increase in trend over time (*P*<0.001). Among other topical agents, 6.5% (102/1569) of MRSA was resistant to fusidic acid. **Conclusion:** As mupirocin resistance gradually increases, a test for mupirocin nesteristics of pediatric patients and 20.3% (692/3414) were mupirocin resistant. Among MRSA, Mupirocin-resistant (MupR) was 22.6% (354/1569), and 40.1% (19/275) patients was 0.14 years (interquartile range 2.0-8.1) (*P*=0.000). Of 692 MupR MRSA was the more commonly isolated in infants younger than one year (77.4%, 274/354), and MupR

Backgrounds

- Mupirocin has been recommended for decolonization in methicillin-resi stant Staphylococcus aureus (MRSA) carriers for recurrent skin and soft tisue infections and treatment for impetigo.
- The indiscriminate use of mupirocin causes mupirocin resistance, associated with decolonization failure.
- The aim of the study was to investigate the epidemiology of mupirocin resistance and to identify clinical characteristics among children in a single center.




Figure 1. Chemical structure of mupirocin

Madden GR, Sifri CD, Curr Infect Dis Rep. 2018
Figure 2. Mechanisms of bactericidal activity
and resistance to mupirocin

upA) prevents mupirocin binding

Methods

- Study periods: January 2011 ~ October 2020
- Study patients: pediatric patients under 19 years old with
 Staphylococcus aureus in whom firstly isolated from any body site
- **Study design**: Retrospectively electronic chart review for the epidemiol ogy of mupirocin resistance and clinical characteristics for *S. aureus*
- Statistical analysis:

Chi-square test or Fisher's exact test for comparing between mupirocin resistance and sensitive group by using the using the SPSS software version 27 (IBM Corp., Armonk, NY, USA)

Abbrivation; t-RNA, transfer ribonucleic acid; *mupA*, mupirocin resistance gene; MupR, mupirocin resistant; MupS, mupirocin sensitive; MRSA, methicillin resistant *S. aureus*; MSSA, methicillin sensitive *S. aureus*; NICU, neonatal intensive care unit; PICU, pediatric intensive care unit; CA, cardiology unit; OPD, outpatient clinic

Figure 3. Overview of patients with S. aureus by resistant to mupirocin and oxacillin

Staphylococcus aureus isolated firstly from any body sites of pediatric patients and tested for mupirocin susceptibility at Samsung Medical Center from Jan 2011 to Oct 2020

N=3,414




 Table 1. Baseline demographics

	MupR <i>S. aureus</i> (N = 692)	MupS <i>S. aureus</i> (N = 2,665)	<i>P</i> -value
Sex, male (%)	405 (58.5%)	1509 (56.6%)	0.368
Median age (IQR)	1.1 (0.1-5.6)	0.5 (0.1-5.3)	0.004
MRSA	0.1 (0.03-0.8)	0.4 (0.07-3.4)	
MSSA	5.0 (2.0-8.1)	0.7 (0.1-7.5)	
Outpatients	378 (55%)	1026 (38%)	< 0.001
Inpatients			
NICU	173 (25%)	844 (32%)	
CA	74 (11%)	253 (9.5%)	
PICU	27 (3.9%)	196 (7.4%)	
Others	40 (5.8%)	346 (13%)	
Body site			< 0.001
Skin	657 (95%)	2226 (84%)	
Respiratory	11 (2%)	167 (6%)	
Blood	2 (0.2%)	103 (4%)	
Sterile site	3 (0.4%)	40 (1.5%)	
GI tract	2 (0.2%)	37 (1.4%)	

Results




Figure 4. No. of patients with mupirocin resistant *S. aureus* by age groups




Figure 5. No. of patients with mupirocin resistant *S. aureus* by locations




Figure 6. Proportion of mupirocin resistance MRSA by year

Summary

- Of the 3,414 S. aureus isolates, 20.3% were mupirocin resistant.
- MupR MRSA was more common in <1 year old group, and MupR MSSA was more common in > 5 year old group.
 - MupR MRSA was detected most commonly in NICU, and MupR MSSA was detected most commonly in OPD.
 - Proportion of MupR MRSA significantly increased over time (P<0.001).

Conclusions

- As mupirocin resistance gradually increases, a test for mupirocin susceptibility should be performed before applying the skin lesions or decolonization for MRSA.
- Furthermore, clinicians should carefully prescribe mupirocin to prevent the development of MupR *S. aureus*.